Abstract
Introduction Maintaining long-term positive airway pressure (CPAP) adherence is a major challenge when treating obstructive sleep apnea (OSA). We evaluated factors associated with one-year CPAP adherence and developed models predicting Month-12 adherence and CPAP-use trajectories.
Methods CPAP-naive adults with OSA (apnea-hypopnea index [AHI]≥5) at Kaiser Permanente Southern California with 364-day observation period were analyzed (development/internal-validation cohort, n=14,906; temporal holdout, n=1,676). Logistic regression evaluated baseline associations with Month-12 adherence (mean≥4 hours/night during days 331-360). XGBoost models utilized baseline features (clinical, sleep-study, questionnaire data), early CPAP-only data (days 1-7), or combined to predict long-term CPAP use. A latent-class model identified trajectories over days 8-364. Predictive models were evaluated in both random and temporal holdouts.
Results About one-third (34.6%) of the primary cohort (49.7±13.8 years, 63.2% male) were adherent during Month-12. Higher AHI and longer self-reported sleep duration favored adherence while greater comorbidity burden, depression, and substance-use disorder were associated with lower adherence. In held-out testing, adherence prediction using baseline features yielded an AUROC of 0.678. Using CPAP-only data, AUROCs were higher from 0.787 with seven days of usage data to 0.816 and 0.854 with 14 and 30 days. Models combining CPAP and baseline features increased Day-7 AUROC to 0.810. We identified four one-year trajectories: Early-Decliners (42.9%), Gradual-Decliners (17.4%), Stable-Moderate (19.0%), Stable-High (20.7%). Models predicting patient trajectory revealed macro-average AUROCs of 0.619, 0.756, and 0.770 for baseline, CPAP-only, and combined models.
Conclusion Baseline pAbstractTextredictors may identify strategies for adherence support, while early CPAP data substantially improved predictive performance. These models may guide personalized follow-up but should not restrict CPAP access. External and implementation validation are needed.
Competing Interest Statement
Dr. Thomas is a co-inventor and patent holder of the ECG-derived sleep spectrogram, which may be used to phenotype sleep quality and central/complex sleep apnea. The technology is licensed by Beth Israel Deaconess Medical Center to MyCardio, LLC. He is also co-inventor and patent holder of the following: 1) Positive Airway Pressure Gas Modulator, being developed as treatment of central/complex sleep apnea; 2) auto-CPAP algorithm; 3) submitted patents licensed to Sleepcare Asia: a) Respiratory Self-Similarity algorithm to detect high loop gain (HLGSA); b) Enhanced Expiratory Rebreathing Space for treatment of HLGSA. He is a consultant for Guidepoint Global and GLG Councils. Dr. Mazzotti has received a research grant from Phillips Healthcare to and research devices from MyCardio, LLC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of Beth Israel Deaconess Medical Center waived ethical approval for this work (#2024P000804/#2022P000417).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Diego R. Mazzotti and Haoqi Sun are co-senior authors.
Data Availability
The individual-level data underlying this study are not publicly available because they contain protected health information. All aggregate results supporting the findings of this study are provided within the manuscript and its supplementary materials.





